These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 17638191

  • 1. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
    Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP.
    Clin Infect Dis; 2007 Aug 15; 45(4):439-47. PubMed ID: 17638191
    [Abstract] [Full Text] [Related]

  • 2. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.
    Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML, Boeckh M.
    J Infect Dis; 2002 Jan 01; 185(1):20-7. PubMed ID: 11756977
    [Abstract] [Full Text] [Related]

  • 3. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
    Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M.
    Lancet; 2000 Aug 19; 356(9230):645-9. PubMed ID: 10968438
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients.
    Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, Pedersen RA, Dierkhising RA, Patel R, Razonable RR.
    J Heart Lung Transplant; 2007 Oct 19; 26(10):1019-24. PubMed ID: 17919622
    [Abstract] [Full Text] [Related]

  • 9. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS.
    Transplantation; 2007 Feb 15; 83(3):290-6. PubMed ID: 17297403
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus infection in heart transplantation: A single center experience.
    Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V.
    Transpl Infect Dis; 2018 Aug 15; 20(4):e12896. PubMed ID: 29602266
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun 15; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 12. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP, Roubinian N, Khan Y, Chin-Hong PV, Singer JP, Golden JA, Miller S.
    Transpl Infect Dis; 2012 Jun 27; 14(3):248-58. PubMed ID: 22385394
    [Abstract] [Full Text] [Related]

  • 14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T, Lai WK, Mutimer D.
    Transpl Infect Dis; 2005 Jun 27; 7(2):57-62. PubMed ID: 16150091
    [Abstract] [Full Text] [Related]

  • 15. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT, Berger SP, Vossen AC, van der Blij-de Brouwer CS, Press RR, de Fijter JW, Claas EC, Kroes AC.
    Transplantation; 2010 Feb 15; 89(3):320-6. PubMed ID: 20145523
    [Abstract] [Full Text] [Related]

  • 16. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 15; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 17. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.
    Bhorade SM, Lurain NS, Jordan A, Leischner J, Villanueva J, Durazo R, Creech S, Vigneswaran WT, Garrity ER.
    J Heart Lung Transplant; 2002 Dec 15; 21(12):1274-82. PubMed ID: 12490272
    [Abstract] [Full Text] [Related]

  • 18. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C, Pineda M, Linares L, Marcos MA, Esteva C, Antón A, Cofán F, Ricart MJ, Navasa M, Pérez-Villa F, Pumarola T, Moreno A.
    Transplant Proc; 2007 Sep 15; 39(7):2228-30. PubMed ID: 17889146
    [Abstract] [Full Text] [Related]

  • 19. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ, Zaas AK, Hanson KE, Palmer SM.
    J Heart Lung Transplant; 2007 Dec 15; 26(12):1286-92. PubMed ID: 18096480
    [Abstract] [Full Text] [Related]

  • 20. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
    Jamal AJ, Husain S, Li Y, Famure O, Kim SJ.
    Transplantation; 2014 Mar 15; 97(5):569-75. PubMed ID: 24398852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.